India’s Healthcare Business Daily
Search the archive
Key Coverage
Follow IndiaMedToday
Topic
1 article
Kopozgo is the first and only oral, selective cardiac myosin inhibitor approved in India Bristol Myers Squibb (BMS) announced the…